Identification of wearing-off manifestations (reduction of levodopa effect) in Parkinson's disease using specific questionnaire and comparison of the results with routine ambulatory evaluations;Identificação de manifestaç ões de wearing-off (redução do efeito da levodopa) em pacientes com doen ça de Parkinson utilizando questionário específico e comparação dos resultados com avaliaçães ambulatoriais de rotina

Arquivos de Neuro-Psiquiatria

Volumn 68, Issue 4, 2010, Pages 506-510

  Melo, Luciano Magalhães ^a   Chien, Hsin Fen ^a   Barbosa, Egberto Reis ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Nonmotor fluctuations; Parkinson's disease; Screening; Wearing off

Indexed keywords

LEVODOPA;

ADULT; AGED; AMBULATORY CARE; AMBULATORY MONITORING; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONSULTATION; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; QUESTIONNAIRE; RISK FACTOR; SCREENING; WEARING OFF PHENOMENON;

EID: 77957325591     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2010000400007     Document Type: Article

References (15)

1. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20:726-733.
2. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease. on chronic levodopa therapy. Lancet 1976;1:292-296.
3. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55(Suppl 4): S13-S20.
4. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med 1998;339:1044-1053.4.
5. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-do pa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239.
6. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(Suppl 1):S1-S9.
7. Grandas F, Galiano ML, Tabernero CJ. Risk factors for levodopa induced dys kinesias in Parkinson's disease. J Neurol 1999;246:1127-1133.
8. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
9. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;18:284:1931-1938.
10. Schrag A, Ben-Shlomo YB, Brown R, Marsden D. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 1998;13:885-894.
11. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease frequent and disabling Neurology 2002;59:408-413.
12. Stacy M, Hauser R. Development of a patient questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. J Neural Transm 2007;114:211-217.
13. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
14. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
15. Richard IH, Frank S, Mcdermott MP, et al. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations Cogn Behav Neurol 2004;17:201-207.